In addition to diagnostic use, PSMA-targeted imaging of ICC may have theranostic potential in combination with PSMA-targeted peptide radioligand therapy (e.g., 177Lu-PSMA-617) in patients with high tumour PSMA expression. The gene discussed is FOLH1; the disease is neoplasm.